Edition:
United Kingdom

TRACON Pharmaceuticals Inc (TCON.OQ)

TCON.OQ on NASDAQ Stock Exchange Global Market

0.66USD
20 Jun 2019
Change (% chg)

$0.02 (+3.12%)
Prev Close
$0.64
Open
$0.63
Day's High
$0.66
Day's Low
$0.63
Volume
448
Avg. Vol
64,922
52-wk High
$3.00
52-wk Low
$0.50

Latest Key Developments (Source: Significant Developments)

Tracon Pharmaceuticals Reports Qtrly Loss Per Share $0.24
Tuesday, 14 May 2019 

May 14 (Reuters) - TRACON Pharmaceuticals Inc ::TRACON PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.TRACON PHARMACEUTICALS INC - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE $32.1 MILLION AT MARCH 31, 2019, COMPARED TO $39.1 MILLION AT DECEMBER 31.TRACON PHARMACEUTICALS INC - EXPECT CURRENT CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TO FUND OPERATIONS INTO Q3 OF 2020.TRACON PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.24.TRACON PHARMACEUTICALS INC - COLLABORATION REVENUE WAS $0 FOR Q1 OF 2019 COMPARED TO $3.0 MILLION FOR Q1 OF 2018.  Full Article

Tracon Pharmaceuticals Announces Termination Of Phase 3 Tappas Trial
Friday, 12 Apr 2019 

April 12 (Reuters) - TRACON Pharmaceuticals Inc ::TRACON PHARMACEUTICALS ANNOUNCES TERMINATION OF PHASE 3 TAPPAS TRIAL BASED ON THE RECOMMENDATION OF THE INDEPENDENT DATA MONITORING COMMITTEE.TRACON PHARMACEUTICALS INC - TRIAL WAS TERMINATED FOR FUTILITY BASED ON RECOMMENDATION OF INDEPENDENT DATA MONITORING COMMITTEE.TRACON PHARMACEUTICALS INC - WILL WORK WITH INVESTIGATORS TO APPROPRIATELY CONCLUDE STUDY.TRACON PHARMACEUTICALS INC - ANTICIPATE CURRENT CASH RUNWAY WILL NOW EXTEND INTO Q3 OF 2020.TRACON PHARMACEUTICALS INC - WILL TERMINATE FURTHER ENROLLMENT IN COMPANY SPONSORED TRIALS OF TRC105 IN ONCOLOGY..TRACON PHARMACEUTICALS INC - WILL CONTINUE TO SUPPORT PARTNER, SANTEN, IN THEIR DEVELOPMENT OF DE-122 IN WET AMD.TRACON PHARMACEUTICALS INC - WILL ALSO CONTINUE TO DEVELOP OTHER DRUG CANDIDATES, INCLUDING TRC253 IN PARTNERSHIP WITH JANSSEN.TRACON PHARMACEUTICALS INC - INTEND TO ADVANCE CANDIDATES WITHIN I-MAB'S BROAD BISPECIFIC PIPELINE INTO CLINIC IN US AS EARLY AS BEGINNING OF NEXT YEAR.  Full Article

Tracon Pharmaceuticals Files For Mixed Shelf Of Upto $100 Mln
Friday, 1 Mar 2019 

March 1 (Reuters) - TRACON Pharmaceuticals Inc ::TRACON PHARMACEUTICALS FILES FOR MIXED SHELF OF UPTO $100 MILLION - SEC FILING.  Full Article

Tracon Pharmaceuticals Reports Fourth Quarter Results
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - TRACON Pharmaceuticals Inc ::TRACON PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR-END 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.TRACON PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.26.  Full Article

Tracon Pharmaceuticals Announces Top-Line Data From Phase 2 Traxar Clinical Trial
Friday, 21 Dec 2018 

Dec 21 (Reuters) - TRACON Pharmaceuticals Inc ::TRACON PHARMACEUTICALS ANNOUNCES TOP-LINE DATA FROM PHASE 2 TRAXAR CLINICAL TRIAL IN RENAL CELL CARCINOMA.TRACON PHARMACEUTICALS INC - INLYTA DID NOT DEMONSTRATE CLINICALLY MEANINGFUL EFFICACY IN PATIENTS WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA.TRACON PHARMACEUTICALS INC - SAFETY PROFILE OBSERVED IN TRAXAR WAS CONSISTENT WITH PREVIOUS STUDIES OF TRC105.TRACON PHARMACEUTICALS - TRC105 IN COMBINATION WITH INLYTA DID NOT MEET PRIMARY ENDPOINT OF IMPROVING PROGRESSION FREE SURVIVAL IN STUDY.TRACON PHARMACEUTICALS - INTERIM ANALYSIS TO DETERMINE FINAL SAMPLE SIZE OF PHASE 3 TAPPAS TRIAL OF TRC105, VOTRIENT IN ANGIOSARCOMA EXPECTED IN Q1 2019.  Full Article

TRACON Pharmaceuticals Reports Q3 Loss Per Share $0.30
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - TRACON Pharmaceuticals Inc ::TRACON PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.TRACON PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.30.TRACON PHARMACEUTICALS - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE $47.2 MILLION AT SEPT 30, VERSUS $34.5 MILLION AT DEC 31, 2017.TRACON PHARMACEUTICALS - EXPECT CURRENT CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TO FUND OPERATIONS INTO Q4 2019.  Full Article

TRACON Pharmaceuticals Announces $38.7 Million Private Placement
Friday, 23 Mar 2018 

March 23 (Reuters) - Tracon Pharmaceuticals Inc ::TRACON PHARMACEUTICALS ANNOUNCES $38.7 MILLION PRIVATE PLACEMENT.TRACON PHARMACEUTICALS - FINANCING LED BY PUISSANCE CAPITAL MANAGEMENT, PARTICIPATION FROM NEW ENTERPRISE ASSOCIATES, 683 CAPITAL PARTNERS, OTHERS.TRACON PHARMACEUTICALS -‍ EXPECTS TO APPOINT TED WANG, CHIEF INVESTMENT OFFICER OF PUISSANCE CAPITAL MANAGEMENT TO BOARD FOLLOWING CLOSE.TRACON PHARMACEUTICALS INC - ‍ TO USE PROCEEDS TO FUND DEVELOPMENT OF TRC105, TO CONTINUE DEVELOPMENT OF OTHER ASSETS SUCH AS TRC253​.  Full Article

TRACON Pharma Qtrly Loss Per Share $0.37
Wednesday, 28 Feb 2018 

Feb 28 (Reuters) - TRACON Pharmaceuticals Inc ::TRACON PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.THERE WAS NO COLLABORATION REVENUE FOR Q4 OF 2017 COMPARED TO $0.6 MILLION FOR Q4 OF 2016.QTRLY LOSS PER SHARE $0.37.Q4 EARNINGS PER SHARE VIEW $-0.46 -- THOMSON REUTERS I/B/E/S.  Full Article

Ambrx And Tracon Pharma Announce Commercialization Agreement For TRC105 In China
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Tracon Pharmaceuticals Inc ::AMBRX AND TRACON PHARMACEUTICALS ANNOUNCE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR TRC105 IN CHINA.AMBRX INC - ENTERED INTO LICENSING AGREEMENT FOR DEVELOPMENT & COMMERCIALIZATION OF TRACON'S PROPRIETARY ENDOGLIN ANTIBODY, TRC105 IN CHINA.AMBRX SAYS TRANSACTION GRANTS AMBRX EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALIZE TRC105 IN ALL INDICATIONS IN CHINA AND TAIWAN.AMBRX SAYS UNDER DEAL TERMS, TRACON WILL RECEIVE AN UPFRONT PAYMENT OF $3 MILLION.AMBRX SAYS TRACON IS ALSO ELIGIBLE TO RECEIVE TIERED ROYALTIES FROM HIGH SINGLE DIGITS TO LOW TEENS ON NET SALES OF TRC105 IN AMBRX TERRITORIES.  Full Article

Tracon Pharmaceuticals announces positive results from phase 1 trial of TRC102, Fludara
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Tracon Pharmaceuticals Inc ::Tracon Pharmaceuticals announces positive results from phase 1 trial of trc102 and fludara® in patients with advanced hematologic malignancy published in oncotarget.Tracon Pharmaceuticals -‍in trial, 4 of 17 patients experienced partial response to treatment, eight additional patients (8/17, 47%) had stable disease​.Tracon Pharmaceuticals -‍in trial, combination of trc102,fludara produced evidence of tumor DNA damage that appeared to correlate with antitumor activity​.  Full Article